<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02708173</url>
  </required_header>
  <id_info>
    <org_study_id>cycdc2015-5</org_study_id>
    <nct_id>NCT02708173</nct_id>
  </id_info>
  <brief_title>Safety Study of Quadrivalent Influenza Virus Vaccine in Healthy People Aged 3 Years and Older</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Chaoyang District Centre for Disease Control and Prevention</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Chaoyang District Centre for Disease Control and Prevention</source>
  <brief_summary>
    <textblock>
      This study evaluates the safety of Quadrivalent Influenza Virus Vaccine in Healthy People
      Aged years 3 to 60.40 Subjects will be equally divided into 2 groups,including 3-17 years old
      and 18-60 years old.Adult group first receive one dose of Quadrivalent Influenza Virus
      Vaccine.Then minors group also receive one dose of Quadrivalent Influenza Virus Vaccine after
      7 days.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of adverse reactions of Quadrivalent Influenza Virus Vaccine</measure>
    <time_frame>3 months</time_frame>
    <description>Adverse reactions associated with vaccine will be observed in subjects after vaccination. Solicited local adverse events include Pain, Redness, Swelling, Induration, Rash, Pruritus at injection site. solicited general adverse events include Fever, Nausea, Vomiting, Diarrhea, Decreased appetite, Be agitated (irritability, abnormal crying), fatigue, allergy</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Quadrivalent Influenza Virus Vaccine</condition>
  <arm_group>
    <arm_group_label>One dose Vaccine in aged 18-60 years old</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One dose of Quadrivalent Influenza Virus Vaccine will be given in aged 18-60 years old.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>One dose Vaccine in aged 3-17 years old</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One dose of Quadrivalent Influenza Virus Vaccine will be given in aged 3-17 years old.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>One dose of Quadrivalent Influenza Virus Vaccine</intervention_name>
    <arm_group_label>One dose Vaccine in aged 18-60 years old</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>One dose of Quadrivalent Influenza Virus Vaccine</intervention_name>
    <arm_group_label>One dose Vaccine in aged 3-17 years old</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy subjects more than 3 years old, and the subjects can be informed consent, and
             sign the informed consent.

          -  the subjects and his guardians can obey the demands of the scheme .

          -  Axillary temperature less than 37℃

        Exclusion Criteria:

          -  The people who has a vaccine allergies, or who allergic to any kind of composition in
             experimental vaccine, such as eggs,ovalbumin etc.

          -  The people who has serious side effects to vaccine, such as allergy,urticaria, skin
             eczema, dyspnea, angioneurotic edema or abdominal pain.

          -  the subject who has symptoms of acute infection within a week.

          -  Autoimmune diseases or Immune function defect, people has immunosuppressive therapy,
             cytotoxic treatment or inhaled corticosteroids in the past 6 months.

          -  People has congenital malformations, developmental disorder or serious chronic
             diseases( such as Down's syndrome, diabetes, Sickle cell anemia or nerve system
             disease)

          -  People has asthma Unstable that need emergency treatment, hospitalization, intubation,
             oral or intravenous corticosteroid in the past 2 years.

          -  Diagnosed abnormal coagulation(Lack of clotting factors,Clotting disorders,Platelet
             abnormality) or significant bruising or coagulopathy

          -  people has history or family history of convulsions, seizures, encephalopathy and
             psychiatric.

          -  alienia, functional asplenia, and alienia or splenectomy in any situation.

          -  Serious neurological disorders such as Green Barry syndrome.

          -  people who has received blood products or immunoglobulin products in the past one
             months.

          -  people who has received other study drug in the past one month.

          -  people who received live attenuated vaccine, subunit vaccine or inactivated vaccine.

          -  people who has received allergy treatment in in the past 14 days.

          -  People who is on anti-TB treatment.

          -  People whose axillary temperature is more than 37℃ before the vaccination.

          -  People who is pregnant.

          -  Any factors unsuitable for clinical trail according to the researchers.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>DongBa clinical center</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 10, 2016</study_first_submitted>
  <study_first_submitted_qc>March 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2016</study_first_posted>
  <last_update_submitted>August 12, 2016</last_update_submitted>
  <last_update_submitted_qc>August 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vaccine</keyword>
  <keyword>safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

